MET and urinary bladder cancer: Our results suggest that further studies are warranted to fully define the prevalence and oncogenic impact of HGF/Met signaling in bladder cancer, and to identify reliable and practical biomarkers of pathway activation for patient selection and predicting response to treatment with HGF/Met targeted therapeutics.